BioCentury | Dec 7, 2020
Politics, Policy & Law

Obamacare advocate Becerra likely to focus on expanding Affordable Care Act, drug pricing as HHS chief

In selecting California Attorney General Xavier Becerra as his HHS secretary nominee, President-elect Joe Biden has signaled his intention to follow through on campaign commitments to extending the Affordable Care Act and giving Medicare the...
BioCentury | Nov 14, 2020
Politics, Policy & Law

Candidates for next FDA commissioner

Four former FDA officials and an oncologist are on a list of candidates President-elect Joe Biden’s team is considering as FDA commissioner, individuals who are advising the transition team told BioCentury....
BioCentury | Nov 3, 2020
Politics, Policy & Law

Regardless of election outcome, changes coming to key Senate committee

While the outcome of Tuesday’s elections may not be known for some time, it is certain that there will be changes in the leadership and composition of a Senate committee that shapes the life sciences...
BioCentury | Oct 2, 2020
Finance

Election volatility may drive investors toward low-risk opportunities in 4Q

The increasing likelihood of a contested U.S. presidential election means the markets could be in for a high dose of volatility in 4Q20, pushing the pause button on a record year for IPOs and sending...
BioCentury | Nov 20, 2019
Politics & Policy

FDA commissioner nominee Hahn sidesteps questions on importation, new approval standards

Senate Health, Education, Labor and Pensions Committee Chairman Lamar Alexander (R-Tenn.) announced Wednesday that he plans to fast-track confirmation of Stephen Hahn as FDA commissioner. The committee will vote on Hahn's confirmation on Dec. 3...
BioCentury | Nov 16, 2019
Regulation

Stephen Hahn’s road to White Oak

The path to Stephen Hahn’s confirmation as FDA commissioner is enveloped in clouds of flavored vapor, littered with piles of Impossible Burgers, and passes tanks filled with precocious fish. The Trump administration’s policies on regulating...
BioCentury | Jun 29, 2019
Finance

Specialists and strong fundamentals must carry the sector in 3Q19

Heading into the third quarter, specialist biotech investors are in the driver’s seat, and their stances on whether to trim or spend in the down market are split. After recovering at the start of the...
BioCentury | May 30, 2019
Politics & Policy

Durbin letter complicates Sharpless’ path to confirmation as FDA commissioner

A scathing letter from Sen. Richard Durbin (D-Ill.), the Democratic Whip, expressing a lack of confidence in acting FDA Commissioner Ned Sharpless could cloud chances for Sharpless to be nominated or confirmed as permanent commissioner....
BioCentury | Jun 1, 2018
Company News

Ironwood shareholders vote to keep board intact

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said its shareholders re-elected all three of its preferred board director nominees during its annual shareholder meeting. Alex Denner, who holds about a 2.2% stake in Ironwood and is chief investment...
BioCentury | May 31, 2018
Company News

Ironwood shareholders opt to keep board intact

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said its shareholders re-elected all three of its preferred board director nominees during its annual shareholder meeting. Alex Denner, who holds about a 2.2% stake in Ironwood and is chief investment...
Items per page:
1 - 10 of 253
BioCentury | Dec 7, 2020
Politics, Policy & Law

Obamacare advocate Becerra likely to focus on expanding Affordable Care Act, drug pricing as HHS chief

In selecting California Attorney General Xavier Becerra as his HHS secretary nominee, President-elect Joe Biden has signaled his intention to follow through on campaign commitments to extending the Affordable Care Act and giving Medicare the...
BioCentury | Nov 14, 2020
Politics, Policy & Law

Candidates for next FDA commissioner

Four former FDA officials and an oncologist are on a list of candidates President-elect Joe Biden’s team is considering as FDA commissioner, individuals who are advising the transition team told BioCentury....
BioCentury | Nov 3, 2020
Politics, Policy & Law

Regardless of election outcome, changes coming to key Senate committee

While the outcome of Tuesday’s elections may not be known for some time, it is certain that there will be changes in the leadership and composition of a Senate committee that shapes the life sciences...
BioCentury | Oct 2, 2020
Finance

Election volatility may drive investors toward low-risk opportunities in 4Q

The increasing likelihood of a contested U.S. presidential election means the markets could be in for a high dose of volatility in 4Q20, pushing the pause button on a record year for IPOs and sending...
BioCentury | Nov 20, 2019
Politics & Policy

FDA commissioner nominee Hahn sidesteps questions on importation, new approval standards

Senate Health, Education, Labor and Pensions Committee Chairman Lamar Alexander (R-Tenn.) announced Wednesday that he plans to fast-track confirmation of Stephen Hahn as FDA commissioner. The committee will vote on Hahn's confirmation on Dec. 3...
BioCentury | Nov 16, 2019
Regulation

Stephen Hahn’s road to White Oak

The path to Stephen Hahn’s confirmation as FDA commissioner is enveloped in clouds of flavored vapor, littered with piles of Impossible Burgers, and passes tanks filled with precocious fish. The Trump administration’s policies on regulating...
BioCentury | Jun 29, 2019
Finance

Specialists and strong fundamentals must carry the sector in 3Q19

Heading into the third quarter, specialist biotech investors are in the driver’s seat, and their stances on whether to trim or spend in the down market are split. After recovering at the start of the...
BioCentury | May 30, 2019
Politics & Policy

Durbin letter complicates Sharpless’ path to confirmation as FDA commissioner

A scathing letter from Sen. Richard Durbin (D-Ill.), the Democratic Whip, expressing a lack of confidence in acting FDA Commissioner Ned Sharpless could cloud chances for Sharpless to be nominated or confirmed as permanent commissioner....
BioCentury | Jun 1, 2018
Company News

Ironwood shareholders vote to keep board intact

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said its shareholders re-elected all three of its preferred board director nominees during its annual shareholder meeting. Alex Denner, who holds about a 2.2% stake in Ironwood and is chief investment...
BioCentury | May 31, 2018
Company News

Ironwood shareholders opt to keep board intact

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said its shareholders re-elected all three of its preferred board director nominees during its annual shareholder meeting. Alex Denner, who holds about a 2.2% stake in Ironwood and is chief investment...
Items per page:
1 - 10 of 253